LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

This study (LuCarbo) tests whether combining lutetium-177 PSMA-617 (a radioactive treatment that targets prostate cancer cells) with carboplatin (a chemotherapy drug) can help men with metastatic castrate-resistant prostate cancer (mCRPC) — cancer that has spread and no longer responds to hormone therapy. This is an early-phase study evaluating safety and early signs of effectiveness. **You may be eligible if...** - You are 18 years or older - You have confirmed prostate adenocarcinoma that has spread and no longer responds to hormone therapy - Your cancer is progressing despite treatment (rising PSA, new lesions on imaging) - You have received certain prior treatments (such as an androgen receptor pathway inhibitor) - You are in reasonably good health with adequate organ function **You may NOT be eligible if...** - You have not had prior standard therapies for mCRPC - You have severe kidney, liver, or bone marrow problems - You have received prior lutetium-177 PSMA therapy or carboplatin - You are taking medications that significantly interact with carboplatin Talk to your doctor to see if this trial is right for you.